NCT04580914已完成不适用
Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 321
- 试验地点
- 47
- 主要终点
- Rate of Primary Safety Events at 1-Month Post-Procedure
研究概览
简要总结
The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of recurrent symptomatic Paroxysmal Atrial Fibrillation (PAF), defined as atrial fibrillation (AF) that terminates spontaneously or with intervention (either procedure or drug therapy) within seven days of onset. Minimum documentation includes the following:
- •a physician's note indicating recurrent self-terminating atrial fibrillation (AF) which includes at least two symptomatic AF episodes in the patient's history within the last 6 months prior to enrollment, and any electrocardiographically documented AF episode within 12 months prior to enrollment.
- •Subjects who are eligible for an ablation procedure for PAF according to 2017 HRS expert consensus statement on catheter ablation of atrial fibrillation;
- •Subjects refractory or intolerant to at least one class I or class III antiarrhythmic medication or contraindicated to any class I or class III medications;
- •Subjects who are willing and capable of providing informed consent;
- •Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center;
- •Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.
排除标准
- •Subjects with New York Heart Association (NYHA) Class III or IV heart failure < 180 days prior to enrollment
- •Left atrial diameter > 5.0 cm or left atrial volume >50 ml/m² indexed based on the most recent echocardiography+
- •Left ventricular ejection fraction < 35% based on the most recent echocardiogram +
- •Continuous AF lasting longer than seven (7) days
- •Subjects who have undergone any previous left atrial cardiac ablation (RF, Cryo, surgical)
- •Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
- •Subjects who have undergone any cardiac ablation or any surgery within 30 days prior to enrollment
- •Currently implanted with a pacemaker, ICD, CRT device, or an implanted arrhythmia loop recorder
- •Active systemic infection
- •Unstable angina or ongoing myocardial ischemia
- •Myocardial Infarction (MI) within 90 days prior to enrollment
- •Evidence of myxoma, left atrial thrombus or intracardiac mural thrombus++
- •Previous cardiac surgery (i.e. ventriculotomy, atriotomy, CABG, PTCA, PCI, coronary stenting procedures) ≤ 90 days prior to enrollment.
- •Severe valvular disease, including mechanical prosthetic mitral or tricuspid heart valves (patients with successful mitral valve repair allowed - annular ring constitutes repair);
- •Any prior history of documented cerebral infarct, TIA or systemic embolism [excluding a post-operative deep vein thrombosis (DVT)] <180 days prior to enrollment
- •Moderate or severe mitral stenosis (severity assessed on the most recent TTE ≤180 days prior to enrollment. Defined as pulmonary artery systolic pressure >30 mmHg)
- •Presence of left atrial appendage closure device
- •Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder
- •Subjects who, in the judgment of the investigator, have a life expectancy of less than two (2) years
- •Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon investigator's discretion)
- •Amiodarone use within 60 days prior to enrollment
- •Any carotid stenting or endarterectomy
- •Stage 3B renal disease or higher (estimated glomerular filtration rate, eGFR <45 mL/min)
- •Known coagulopathy disorder (e.g. von Willebrand's disease, hemophilia)
- •Any known contraindication to an AF ablation
- •Any known contraindication for anticoagulation (e.g. patients unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation)
- •Vena cava embolic protection filter devices and/or known femoral thrombus that prevents catheter insertion from the femoral approach
- •Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
- •Rheumatic Heart Disease
- •Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
- •Subjects unable or unwilling to complete follow-up visits and examinations for the duration of the clinical study
- •Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility.
- •LVEF and LA diameters obtained ≤180 days prior to enrollment will be acceptable, unless a cardiac event has occurred (e.g. MI) between the date of the exam and the enrollment date. In this case, a new echocardiogram (trans-thoracic or trans-esophageal, or intracardiac echo) must be performed to confirm eligibility prior to performing ablation. If no recent (≤180 days prior to enrollment) echocardiogram is available at the time of the enrollment, a new echocardiogram must be performed either prior to enrolling the patient into the study or post-consent to confirm patient's eligibility prior to performing the ablation. For TTE, LA anteroposterior diameter measured by M-mode from the parasternal long-axis view will be used. If both LA diameter and volume are available and at least one of them meets the exclusion criteria, the subject is considered ineligible for the study.
- •The absence of thrombus must be confirmed by means of a trans-esophageal echocardiogram (TEE) within 48 hours prior to the procedure or Intracardiac Echography (ICE) during the procedure in subjects not adequately anticoagulated per Section 10.4.
- •If a thrombus is observed, the subject no longer meets eligibility criteria and should be considered "Consent Ineligible".
研究组 & 干预措施
Treatment with Ablation Catheter
Experimental
Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
干预措施: Treatment with IntellaNav StablePoint Ablation Catheter (Device)
结局指标
主要结局
Rate of Primary Safety Events at 1-Month Post-Procedure
时间窗: Up to 30 Days
The primary safety endpoint at 30 days is defined as the safety event-free rate at 1-Month (30 days) post-procedure.
Rate of Primary Safety Events at 12-Months Post-Procedure
时间窗: 12 Months
The primary safety endpoint at 12 months is defined as the safety event-free rate at 12 months post-procedure.
Percentage of Participants With Freedom From Treatment Failure at 12-Months Post-Procedure
时间窗: 12 Months
The twelve-month effectiveness endpoint is defined as the event-free rate at twelve-month post-procedure.
Number of Participants That Achieved Electrical Isolation of All Pulmonary Veins
时间窗: 30 Days
The primary effectiveness endpoint of acute procedural success is defined as the achievement of electrical isolation of all PVs using the IntellaNav StablePoint catheter only.
次要结局
- Rate of SAEs Through 12-Months Post-Procedure(12 Months)
- Percentage of Participants With Freedom From Primary Effectiveness Failure Without a Repeat Procedure(12 Months)
- Rate of AEs Through 12-Months Post-Procedure(12 Months)
- Number of Patients With New or Increased Dose of AAD(12 Months)
- Percentage of Participants With Freedom From Documented Symptomatic Atrial Fibrillation, Atrial Flutter and Atrial Tachycardia Recurrence(12 Months)
研究者
研究点 (47)
Loading locations...
相似试验
已完成
不适用
Clinical Evaluation of the StablePoint Catheter and Force-Sensing System for Paroxysmal Atrial FibrillatioAtrial Fibrillation - Abnormal heart rhythm10007521NL-OMON50243Boston Scientific20
进行中（未招募）
不适用
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm TreatmentIntracranial AneurysmNCT04999423Microvention-Terumo, Inc.206
已完成
不适用
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural CatheterMalignant Pleural EffusionNCT02649894C. R. Bard119
终止
不适用
Evaluation of the Safety and Clinical Performance of the Connected Catheter StudyChronicUrinary RetentionNCT05330598Spinal Singularity26
已完成
不适用
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural EffusionsMalignant Pleural EffusionsNCT02227732C. R. Bard10